NovaBridge Biosciences (NBP) Liabilities and Shareholders Equity (2018 - 2026)

NovaBridge Biosciences (NBP) has reported Liabilities and Shareholders Equity for 8 consecutive years, with $260.5 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Liabilities and Shareholders Equity rose 22.49% year-over-year to $260.5 million; the TTM figure through Dec 2025 stood at $953.6 million (up 36.38% YoY), while the FY2025 annual figure was $260.5 million, up 22.49% from the prior year.
• Liabilities and Shareholders Equity eased to $260.5 million in Q4 2025 per NBP's latest filing, from $277.4 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $952.2 million in Q2 2021 and bottomed at $206.7 million in Q2 2025.
• Historically, Liabilities and Shareholders Equity has averaged $436.5 million across 5 years, with a median of $277.4 million in 2025.
• Annual changes were most pronounced in 2021 — Liabilities and Shareholders Equity surged 228.37% — and 2024, when it tumbled 49.37%.
• NovaBridge Biosciences' Liabilities and Shareholders Equity stood at $876.1 million in 2021, then plunged by 34.62% to $572.8 million in 2022, then slumped by 36.64% to $362.9 million in 2023, then tumbled by 41.4% to $212.7 million in 2024, then climbed by 22.49% to $260.5 million in 2025.
• Business Quant data shows NBP's Liabilities and Shareholders Equity at $260.5 million in Q4 2025, $277.4 million in Q3 2025, and $206.7 million in Q2 2025.